Form D · Pharmaceuticals

Aralez Pharmaceuticals Inc.

Vancouver, A1 · CIK 0001660719

Offering snapshot reported Feb 19, 2016 · SEC filing

Reported sold
$75M
Offering amount: $75M
Investors reported
3
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Feb 5, 2016
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Feb 19, 2016Initial$75,000,000No comparison3SEC filing

Offering details

Securities
Debt, Option to acquire, Security to be acquired, Other
Exemptions
06b
Duration over one year
No
Business combination
Yes
Sales commissions
$0
Finders' fees
$0
Form D file number
021-257798
Each Senior Secured Convertible Note bears interest at 2.5% for up to 6 years with the "Conversion Price" defined in the 3 convertible notes.

Source: Form D, filed Feb 19, 2016. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Adrian Adams Director, Executive
Jennifer L. Armstrong Executive
Jason M. Aryeh Director
Scott J. Charles Executive
Neal F. Fowler Director
Mark A. Glickman Executive
Rob Harris Director
Arthur S. Kirsch Director
Andrew I. Koven Executive
Kenneth B. Lee Jr. Director
Seth A. Rudnick, M.D. Director
F. Martin Thrasher Director
Eric L. Trachtenberg Executive
James P. Tursi, M.D. Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
2800 Park Place, 666 Burrard Street
Vancouver, A1, V6C 2Z7